Amrutanjan Health Care Past Earnings Performance
Past criteria checks 3/6
Amrutanjan Health Care has been growing earnings at an average annual rate of 11.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 10.6% per year. Amrutanjan Health Care's return on equity is 16.8%, and it has net margins of 11.2%.
Key information
11.7%
Earnings growth rate
11.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 10.6% |
| Return on equity | 16.8% |
| Net Margin | 11.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Pinning Down Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) P/E Is Difficult Right Now
May 03
Amrutanjan Health Care (NSE:AMRUTANJAN) Has Affirmed Its Dividend Of ₹1.00
Feb 12Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹2.60
Sep 02Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 19Amrutanjan Health Care (NSE:AMRUTANJAN) Is Due To Pay A Dividend Of ₹2.60
Aug 05Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹1.00
Feb 17Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹1.00
Nov 08Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹2.60
Aug 18Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 30Should You Be Adding Amrutanjan Health Care (NSE:AMRUTANJAN) To Your Watchlist Today?
Apr 08Introducing Amrutanjan Health Care (NSE:AMRUTANJAN), The Stock That Zoomed 162% In The Last Five Years
Mar 11Trade Alert: The Non-Executive Independent Director Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN), Govindan Raghavan, Has Just Spent ₹72k Buying A Few More Shares
Feb 24Is It Smart To Buy Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Before It Goes Ex-Dividend?
Feb 14Is Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Latest Stock Performance A Reflection Of Its Financial Health?
Feb 12Is Amrutanjan Health Care Limited (NSE:AMRUTANJAN) A Smart Choice For Dividend Investors?
Jan 30
Is There More To The Story Than Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings Growth?
Jan 17Here's Why I Think Amrutanjan Health Care (NSE:AMRUTANJAN) Is An Interesting Stock
Jan 04What Type Of Shareholders Make Up Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Share Registry?
Dec 22How Much is Amrutanjan Health Care's (NSE:AMRUTANJAN) CEO Getting Paid?
Dec 09If You Had Bought Amrutanjan Health Care (NSE:AMRUTANJAN) Stock Five Years Ago, You Could Pocket A 106% Gain Today
Nov 26Here's What We Like About Amrutanjan Health Care's (NSE:AMRUTANJAN) Upcoming Dividend
Nov 14Why Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Should Be In Your Dividend Portfolio
Oct 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Amrutanjan Health Care Limited's NSE:AMRUTANJAN) Stock?
Oct 10I Ran A Stock Scan For Earnings Growth And Amrutanjan Health Care (NSE:AMRUTANJAN) Passed With Ease
Sep 22What Percentage Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares Do Insiders Own?
Sep 01With Amrutanjan Health Care Limited (NSE:AMRUTANJAN) It Looks Like You'll Get What You Pay For
Aug 11Have Insiders Been Selling Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares?
Jul 29Revenue & Expenses BreakdownBeta
How Amrutanjan Health Care makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3,946 | 440 | 398 | 0 |
| 30 Sep 23 | 3,753 | 373 | 461 | 0 |
| 30 Jun 23 | 3,865 | 432 | 973 | 0 |
| 31 Mar 23 | 3,798 | 398 | 493 | 0 |
| 31 Dec 22 | 3,860 | 418 | 500 | 0 |
| 30 Sep 22 | 3,990 | 517 | 494 | 0 |
| 30 Jun 22 | 3,986 | 588 | 1,037 | 0 |
| 31 Mar 22 | 4,059 | 672 | 505 | 0 |
| 31 Dec 21 | 3,935 | 627 | 1,211 | 0 |
| 30 Sep 21 | 3,829 | 631 | 1,159 | 0 |
| 30 Jun 21 | 3,644 | 668 | 966 | 0 |
| 31 Mar 21 | 3,330 | 612 | 497 | 0 |
| 31 Dec 20 | 2,984 | 589 | 763 | 0 |
| 30 Sep 20 | 2,811 | 474 | 777 | 0 |
| 30 Jun 20 | 2,635 | 322 | 809 | 0 |
| 31 Mar 20 | 2,617 | 251 | 834 | 0 |
| 31 Dec 19 | 2,876 | 314 | 833 | 0 |
| 30 Sep 19 | 2,751 | 274 | 804 | 0 |
| 30 Jun 19 | 2,621 | 257 | 750 | 0 |
| 31 Mar 19 | 2,535 | 250 | 756 | 0 |
| 31 Dec 18 | 2,406 | 158 | 785 | 0 |
| 30 Sep 18 | 2,335 | 168 | 762 | 0 |
| 30 Jun 18 | 2,288 | 201 | 710 | 0 |
| 31 Mar 18 | 2,203 | 200 | 671 | 0 |
| 31 Dec 17 | 2,247 | 165 | 722 | 0 |
| 31 Mar 17 | 2,240 | 211 | 710 | 0 |
| 31 Mar 16 | 1,867 | 206 | 505 | 0 |
| 31 Mar 15 | 1,666 | 149 | 468 | 0 |
| 31 Mar 14 | 1,417 | 124 | 508 | 1 |
Quality Earnings: AMRUTANJAN has high quality earnings.
Growing Profit Margin: AMRUTANJAN's current net profit margins (11.2%) are higher than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMRUTANJAN's earnings have grown by 11.7% per year over the past 5 years.
Accelerating Growth: AMRUTANJAN's earnings growth over the past year (5.2%) is below its 5-year average (11.7% per year).
Earnings vs Industry: AMRUTANJAN earnings growth over the past year (5.2%) did not outperform the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: AMRUTANJAN's Return on Equity (16.8%) is considered low.